In the 25 years since the first World AIDS Day, patient outcomes have improved significantly, but the long-sought-after vaccine remains elusive. As the world commemorated the event this week, two very different projects outlined their plans to combat the virus.
California's PaxVax has picked up $22 million in venture cash to get an oral cholera vaccine into the FDA's hands, working its way through late-stage trials for the single-dose treatment.
Once-rival researchers from the Fred Hutchinson Cancer Research Center and Memorial Sloan-Kettering Cancer Center have decided to join forces and dive into drug development, hauling in a massive $120 million Series A round to advance "smart" T cells that spur an immunologic attack on cancers.
Amid scorn and scrutiny from the FDA, 23andMe is facing a class-action lawsuit claiming the company misled customers in selling genetic tests with no real scientific value, and plaintiffs want at least $5 million in damages.
At the Georgia Institute of Technology and Emory University, researchers are looking for a new way to treat rotator cuff injuries, a common baseball shoulder ailment that has ended many a star pitcher's career.
Lantus is the best-selling diabetes drug in the world right now and the top-selling drug for Sanofi. But the drug goes off patent in 2015, so the French drugmaker is coming on strong with its Lantus successor, known as U300.
Hospira and its biosimilar partner Celltrion won European approval for the first biosimilar of a monoclonal antibody therapy in September when t he EU signed off on their Inflectra, a biosimilar of Johnson & Johnson's Remicade. But despite the achievement, the partners still face a huge challenge: getting doctors to use the drug.
The world's largest drug developers are getting less and less from their R&D spends, according to a report, struggling to deal with ever-escalating development costs as returns diminish.
Despite a major setback earlier this year when the FDA rejected Novo Nordisk's application for Tresiba, forcing a new cardio study, the Danish pharma company's CEO is boasting that the company has a strong R&D effort underway.
Seattle-based Blaze Bioscience has rounded up $9 million in venture cash from a wide circle of angel investors willing to back the biotech's push into the clinic with its first "tumor paint" product.